Metabolic complications of antiretroviral therapy in HIV-infected children.
The purpose of this review is to describe the metabolic complications associated with antiretroviral therapy in HIV-infected children. As a result of extensive research over the last 10 years, there is a greater awareness and understanding of these conditions. However, in resource-limited settings, where the majority of HIV-infected children live, the prevalence and risk factors of metabolic complications are largely unknown. Limited diagnostic resources contribute to this impediment. Therapies for these conditions are still under investigation, including prevention and optimal treatment of reduced bone mineral density, osteopaenia and osteoporosis. Future research goals should be directed towards closing the diagnostic and treatment gaps between rich and poor settings.
Eley
Brian
B
University of Cape Town, Red Cross Children's Hospital and the School of Child and Adolescent Health, Rondebosch, 7701, Cape Town, South Africa. brian.eley@uct.ac.za
D050154:Adiposity / Q000187:drug effects; D000818:Animals; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D001847:Bone Diseases / Q000139:chemically induced / Q000378:metabolism; D002648:Child; D015658:HIV Infections / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D007333:Insulin Resistance; D043322:Lactase / Q000378:metabolism; D052439:Lipid Metabolism Disorders / Q000139:chemically induced / Q000378:metabolism; D008659:Metabolic Diseases / Q000139:chemically induced* / Q000188:drug therapy / Q000378:metabolism; D028361:Mitochondrial Diseases / Q000378:metabolism
D043322:Lactase